June 13, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
CHICAGO — In patients being treated for hypertension, those taking a GLP-1 receptor agonist had higher rates of hypotensive events compared with those not taking one, researchers reported at ENDO 2026. “I began to notice multiple patients in clinic who were started on GLP-1s (by me and others) who were complaining of lightheadedness, dizziness and fainting. They had low blood pressure on my
Questo articolo non è idoneo per il formato TL;DR di Warptech Tech News. È un articolo medico-sanitario (studi su GLP-1 e ipotensione) senza nessuna implicazione per manager IT, CTO, o decisioni tech/business. La struttura richiesta (Frase 2: "perché conta per un manager tech") non ha spunti pertinenti. Se arriva in coda editoriale, consiglio **reject** — oltre scope della testata.
June 13, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

GLP-1 and SGLT2 Users Face Different Risk for Diabetic Foot Complication

New Study Suggests GLP-1 Use Might Lower Your Chances Of Developing This Common Cancer

Monthly GLP-1 for Obesity Promising as More Manageable Alternative

FDA warns telehealth companies over compounded GLP-1s

Large Study Links GLP-1s to Lower Risk of Multiple Cancers

Data collected from a number of clinical trials found that despite recent “buzz,” there is no significant link between GLP-1…

CHICAGO — Major diabetic foot complications were more common in patients with type 2 diabetes treated with SGLT2 inhibitors than…

CHICAGO — In patients with obesity, exercise as assessed by wearable-measured activity declined after they initiated GLP-1…

CHICAGO — Patients with idiopathic intracranial hypertension lost weight and had fewer headaches with GLP-1 receptor agonists,…

Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients…

Use of GLP-1s was associated with significantly reduced risk for hepatic complications among patients with metabolic…